The Ultimate Pill?

摘要

French drug titan sanofi-aventis, newly formed in a $64 billion merger, is getting ready to market a pill called Acomplia that will—say its boosters—help people lose weight, quit smoking and avoid heart attacks. Approval from the Food & Drug Administration is expected within a year. "In three years," says Christopher Cannon, a cardiologist at Boston's Brigham & Women's Hospital, "it will be the number one drug in the world." (Cannon is working on a separate trial for Sanofi's blood thinner Plavix.)